Acalabrutinib, approved for Relapsed or Refractory Mantle-Cell Lymphoma, is an inhibitor of Bruton tyrosine kinase (BTK) acting by MAR with the thiol in Cys481 (Patel et al., 2017). Here, BTK is linked to mantle cell lymphoma.